Decreased histone H2B monoubiquitination in malignant gastric carcinoma

Table 1 Immunohistochemical detection of uH2B modification levels and gastric cancer clinicopathological parameters

Parameter	n	IHC Staining Level			u/H1	P value
		Negative	Low	High
Age (yr)					3059.000	0.969
< 60	93	10	62	21
≥ 60	66	15	29	22
Sex					2728.000	0.373
Male	100	13	59	28
Female	59	12	32	15
Tumor differentiation					40.376	< 0.001
Well	23	1	7	15
Moderate	55	7	22	26
Poor	81	17	62	2
Lauren classification					933.000	< 0.001
Intestinal	60	6	21	33
Diffuse	59	17	35	7
Lymph node metastasis					2330.000	0.049
Absent	53	2	35	16
Present	106	23	56	27
TNM stage					12.896	0.005
I	15	1	6	8
II	20	2	15	3
III	99	14	55	30
IV	25	8	15	2

¹u represents the test statistic of the Kruskal-Wallis H test and H represents the Wilcoxon ranks sum test. IHC: Immunohistochemistry.

Table 2 Multivariate analysis for prognostic factors in gastric cancer-specific survival of patients

Variable	Comparison	RR	95% CI	P value
Age (yr)	< 60 vs≥ 60	0.761	0.493-1.174	0.217
Sex	male vs female	0.961	0.618-1.494	0.858
Tumor differentiation	Well vs moderate, poor	0.497	0.301-0.819	0.006
Lymph node metastasis	Present vs absent	3.274	1.728-6.201	< 0.001
TNM stage	I vs II, III, IV	1.695	1.112-2.583	0.014
uH2B modification	IHC stain positive vs negative	0.400	0.237-0.677	0.001